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IN a previous communication from this laboratory (Roe and Salaman, 1955,
p. 193) it was reportedthat applications to the dorsal skin ofthe mouse of/8-propio-
lactone and croton oil, alternately at 3- to 4-day intervals, gave rise to significantly
morepapillomatathan equivalent treatment with croton oil only. Itwas concluded
that fi-propiolactone is, like urethane (Salaman and Roe, 1953; Graffi et al.
1953; Berenblum and Haran, 1955), triethylene melamine (Roe and Salaman,
1955), and 1,2-benzanthracene (Graffi et al., 1953; Roe and Salaman, 1955), an
initiator of carcinogenesis in mouse-skin.
It was pointed out (Roe and Salaman, 1955, p. 198) that in the group of mice
treated with both /3-propiolactone and croton oil papillomata appeared as early
as the second week of croton oil treatment. This early appearance ofpapillomata,
and the fact that 4 malignant tumours were present in 19 survivors only 25 weeks
from the beginning of the experiment*, suggested that ,¢-propiolactone might
prove to be carcinogenic for mouse-skin, as it is for the subcutaneous tissues of
the rat (Walpole et al., 1954).
In an addendum (Roe and Salaman, 1955, p. 201) an experiment was described
in which 10 mice were painted weekly for over 20 weeks with 2-5 per cent f-propio-
lactone only. No tumours were observed in these mice up to the time ofgoing to
press. However, tumours began to appear at a later date, and details of these are
given below in the first experimental section.
A second possible explanation of the early appearance of papillomata and
malignant tumours in the mice treated with 8-propiolactone and croton oil is
that the scarring caused by the first two applications ofthe former (at 10 per cent
and 5 per cent, respectively) exerted a promoting effect on tumour production.
This possibility is investigated in the latter part of the first experimental section
below.
In an attempt to correlate the ability to initiate tumour-formation in mouse
skin and certain other properties (Roe and Salaman, 1955, p. 198) it was suggested
that there is a positive correlation between tumour-initiating activity for mouse
skin and adenoma-inducing activity for mouse lung. However, as reported in
the addendum referred to, only 1 adenoma was seen at post-mortem in 18 mice
painted with f,-propiolactone and croton oil.
A possible explanation of the failure of skin-applications of ,-propiolactone
to give rise to lung tumours is that it may be totally detoxicated in the skin, with
* Four more malignant tumours arose in this group of mice between the 25th and 30th weeks.
Altogether 6 mice bore malignant tumours, 2 of them bearing 2 each. All the 8 malignant tumours
were of epithelial origin, and had penetrated the panniculus carnosus; no metastases were seen.
The experiment was terminated at the end of the 30th week.F. J. C. ROE AND O. M. GLENDENNING
the result that none reaches the lung in an active form. To exclude this possibility
an experiment was designed in which ,f-propiolactone was administered intra-
venously via the tail vein. The local effect on the skin at the injection site, and the
effect on lung tumour formation, of the intravenous injection of fl-propiolactone
are described in the second experimental section.
MATERIALS AND METHODS
Mice.-Male and female stock albino mice of the "S" strain were used.
Details of the care, feeding, and vaccination as a precaution against ectromelia,
are given in a previous communication (Roe and Salaman, 1955).
Chemical substances and their administration.-The sources of /8-propiolactone,
croton oil, and acetone, and the technique of application to the skin, have been
fully described elsewhere (Roe and Salaman, 1955).
Before intravenous injection mice were warmed in an incubator at 37° C. for
a few minutes. Injection was made into the dorsal vein about 3 cm. from the base
of the tail (proximal to the scar made by previous vaccination).
Methods.-The methods used for the recording of skin tumours, for the exami-
nation ofmiceforlungtumours atpost-mortem, andforthehistologicalexamination
of tissues, are fully described in a previous communication. (Roe and Salaman,
1955).
EXPERIMENTAL
I. The Carcinogenic Effect of /-propiolactone on Mouse Skin
(a) The effect of fi-propiolactone applied repeatedly at a subulcerative concentration
(2.5 per cent)
Ten mice were painted weekly with 0.3 ml. 2.5 per cent fl-propiolactone in
acetone for 52 weeks. During this period and for 3 weeks afterwards mice were
examined at weekly intervals for tumours of the skin.
One mouse died after 5 weeks, the remaining 9 lived until 47 applications had
been given. In these, papillomata began to appear after 27 applications, and
altogether 5 mice bore papillomata. During the 40th week one papilloma on each
of 2 of these 5 mice underwent a malignant change. Both tumours were removed
surgically under anaesthesia, but both recurred. One metastasised to regional
glands. Three weeks after the end of treatment (55th week) there were only 4
survivors, and these had to be killed because of their poor general condition.
The two malignant tumours were examined histologically; one was a highly
anaplastic carcinoma and the other a moderately well-differentiated tumour.
Both had penetrated the panniculus carnosus. Fig. 1 and 2 were prepared from
a section of the more differentiated tumour.
Histological examination showed that two other tumours had infiltrated the
dermis but had not reached the panniculus carnosus. These were regarded as
"probably" malignant (Roe, 1956).
(b) The effect of early scarring, due to high concentration of /3-propiolactone, on the
carcinogenic effect of repeated applications of the latter
Twenty mice were given 5 weekly applications of 8-propiolactone at concen-
trations sufficient to produce and maintain moderate ulceration and scabbing on
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a majority of the mice (10, 5, 5, 10, and 5 per cent respectively). Since then,
weekly applications of ,-propiolactone have been continued at a sub-ulcerative
concentration (2.5 per cent). During this latter treatment the ulcers and scabs
caused by the earlier treatment disappeared in all mice except one. The remaining
mouse was left with a curved linear scar, 2-5 cm. long, which passed diagonally
across the back from the left scapula to the middle ofthe haunches, and remained
clearly visible. Seven weeks after the beginning oftreatment apapilloma appeared
alongside the scar, a second papilloma appeared in a similar position after 12
weeks, and a third 3 weeks later. All three tumours, arranged in a line alongside
the scar, were sessile and grew rapidly. By the 21st week all were ulcerated and
obviously malignant. Themousewaskilled 2weekslater. Histologicalexamination
showed the central tumour to be an anaplastic carcinoma, and the other two to be
squamous carcinomata. All had penetrated the panniculus carnosus, but no
metastases were seen.
A second mouse, in which no visible scar persisted, developed a papilloma on
the back during the 22nd week ofthe experiment. This tumour enlarged steadily,
and by the 31st week appeared malignant to the naked-eye. By this time a
second tumour, a papilloma, had appeared. Two weeks later the mouse died, but
advanced post-mortem changes were present when its death was discovered, and
no sections could be taken of the two tumours.
The experiment is at present in its 40th week, and there are 4 mice still alive.
Thirteen mice have so far died tumourless.
It is concluded thatfl-propiolactone applied repeatedly over a period is carcino-
genic for mouse skin. Not many tumours arise, but most ofthose that do undergo
malignant transformation within a few weeks of their first appearance.
A scar caused by the application offi-propiolactone in high concentration was
the site of3tumours, all ofwhich appearedearlyandallofwhichbecamemalignant.
II. The effects of Intravenous Injection of/3-propiolactone
(a) Formation of skin tumours at the site of intravenous injection of
f-propiolactone
The purpose of the following experiment was to determine whether the intra-
venous administration offl-propiolactone to mice would lead to the formation of
lung tumours. Although the results in this respect were negative (vide infra),
the early appearance oftumours ofthe skin at the site ofinjection on the tail was
thought worthy of description.
Thirty-two mice were injected intravenously by the tail vein with 8J-propio-
lactone in sterile Ringer solution as follows:
1 mg./0.1 ml. ( 3 mice.)
3 ,, 3,, ,, ( 33 ,,)
5 ,, /,, ,, (10 ,, and 3 mice.)
6 ,, /0.2 ,, ( 3 ,,)
10 ,, /,, ,, (107 ,,)
Three ofthe mice given 10 mg. ,-propiolactone became miserable and hunched
during the 24 hours after injection. Two of these recovered during the next few
days, the third, and another mouse which at first appeared well, died. None ofthe
359F. J. C. ROE AND O. M. GLENDENNING
other mice showed any signs of general intoxication. The tails of almost all the
mice showed moderate or severe inflammatory changes in the neighbourhood ofthe
site of injection. In 13 mice this inflammation proceeded to gangrene and the
partial or complete loss of the tail. The records of a few of the mice which lost
their tails indicated that some of the injected material had been accidently intro-
duced outside the vein; in the others, where no appreciable extravenous injection
occurred, it is thought probable that some of the material leaked out of the vein
after injection. Obvious scars persisted at the site of injection on 15 of the 17
survivors which retained their tails. Papillomata arose at the edges of these scars
in 3 mice; the first, 8 weeks after the injection of 5 mg. /-propiolactone; the
second, 9 weeks after the injection of 10 mg.; and the third, 15 weeks after the
injection of 1 mg. (Fig. 3). The first of these three mice developed two further
papillomata close to the scar; these persisted for several weeks, but eventually
sloughed off when the area of skin which bore them became ulcerated. Forty
weeks after injection this mouse was killed; sections taken from the ulcerated
area showed chronic inflammatory changes only. The mouse which developed a
papilloma at the injection site after 9 weeks developed a second similar tumour on
the skin ofthe base ofthe tail overlying the vein into which the injection was made,
but some distance from the point of insertion of the needle (Fig. 4). During the
48th week the first tumour in this mouse began to expand rapidly, and two
weeks later the tail was amputated. Histologically the tumour, which had
invaded the vertebrae, consisted of spindle cells of uncertain origin.
(b) Failure to induce the formation of lung tumours by the intravenous injection of
/3-propiolactone
As described in the previous section a total of 32 mice were given a single
intravenous injection, via the tail vein, of ,-propiolactone in sterile Ringer
solution, in doses ranging from 1 to 10 mg.
Six months after injection 18 of the 26 survivors were killed and examined
post-mortem for the presence of lung adenomata. (The remaining 8 mice are still
under observation.) One mouse bore 5 lung tumours, 4 mice bore one each, and
13 mice bore none. This incidence of pulmonary adenomata is within normal
limits for untreated mice of the same strain and sex.
It is concluded that single intravenous injections of ,8-propiolactone, in doses
ranging from 1 to10 mg., do not increase the incidence of pulmonary adenomata
in "S "' strain mice. On the other hand, contamination of the skin and of the
subcutaneous tissues during the intravenous injection of /l-propiolactone into the
EXPLANATION OF PLATES.
FIG. 1 and 2.-Squamous-cell carcinoma which arose on the back of a mouse after 40 weekly
applications of 2-5 per cent 3-propiolactone in acetone. Fig. 1 shows tumour tissue reaching
down to the level of the panniculus carnosus. x 12. Fig. 2 shows infiltration by tumour
cells of this muscle layer. x 270. [Staining: Haematoxylin and hosin-Biebrich-scarlet
(Salaman and Gwynn, 1951).]
FIG. 3.-Papilloma which arose 15 weeks after the intravenous injection, by the tail vein,
of 1-0 mg. 3-propiolactone in 0.1 ml. sterile Ringer solution.
FIG. 4.-Papillomata on the tail of a mouse following intravenous injection of 10 mg. 3-
propiolactone in 0.2 ml. sterile Ringer solution. The larger, more distal, tumour is situated
at the site of injection; the smaller tumour has arisen from the skin overlying the injected
vein.
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tail vein, or scarring following such contamination, favours the early development
of papillomata at or near the site of injection.
DISCUSSION
Theresults oftheexperiments described above areclear-cut: (i)f,-propiolactone
is carcinogenic for mouse-skin, (ii) scarring of the skin caused by high concentra-
tions off/-propiolactone predisposes to the early appearance of tumours, and (iii)
the intravenous administration of/-propiolactone in doses up to 10 mg. does not
increase the incidence of pulmonary tumours in mice.
Walpole et al. (1954) described the occurrence of local sarcomata in rats
following repeated subcutaneous injections offi-propiolactone. The finding that
thesame substance is carcinogenic for mouse-skin is therefore not entirely unex-
pected. Nevertheless the fact that this simple substance (molecular weight - 72)
is carcinogenic for two different tissues in two distinct species is of considerable
interest.
The fact that tumours arose in relation to scars caused by high concentrations
off/-propiolactone may be explained in one of two ways: the five weeks of treat-
ment at high concentrations offl-propiolactone may have been disproportionately
more effective than prolonged treatment at a lower concentration, or the
scarring which resulted from the high concentration may have promoted the
early appearance oftumours. The close proximity ofthe tumours to the scars, both
on the back and at the site ofinjection on the tail, suggest that scarring had some
tumour-promoting effect. Such an effect has been the subject of many researches
in the past (Pullinger, 1943, 1945a, 1945b; Linell, 1947). Further studies of the
effect of scarring on the carcinogenic action offl-propiolactone are planned.
In the experiments described above the first papilloma in a mouse painted
with fi-propiolactone alone appeared 7 weeks after 120 mg. had been applied. It
is possible that this dose was in excess ofthat required to produce tumours. Never-
theless it is probable that the carcinogenicity off,-propiolactone is of a low order
compared with that of 9,10-dimethyl-1, 2-benzanthracene (DMBA); for instance,
a single application (0.3 mg.) of which has been shown to give rise to benign and
malignant skin tumours (Roe, 1956). Compared with its apparently weak carcino-
genic action the tumour-initiating action of ,B-propiolactone is strong: a single
application of 7-5 mg. followed by 18 weekly applications of croton oil (0.3 ml.,
0.5 per cent) gave rise to 22 papillomata* on 9 surviving mice (Roe and Salaman,
1955, p. 201). Its weakness as a carcinogen for mouse skin may be due to a
deficiency in promoting power. This suggestion is supported by an experiment
of our colleague Mr. R. H. Gwynn (1954, unpublished data). He applied 0-72 per
cent ,-propiolactone weekly, following a single initiating dose of DMBA. No
tumours appeared during '20 weeks of treatment, and he concluded that fl-prop-
iolactone at this concentration does not promote tumour development. On the
other hand the fact that ,-propiolactone may give rise to tumours of mouse-skin
by itselfindicates that it is not entirely devoid of promoting activity, as appears
to be the case with urethane (Salaman and Roe, 1953).
It has been suggested (Roe and Salaman, 1955) that there is a positive corre-
lation between tumour-initiating activity for mouse skin and adenoma-inducing
* After 41 weeks, one of these papillomata showed signs of malignancy, and on microscopic
examination showed penetration of the panniculus carnosus.
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activity for mouse lung. The classical report of Andervont and Shimkin (1940)
indicated that the intravenous route is suitable for testing substances for carcino-
genic action on mouse lung, and therefore the failure to produce lung tumours in
mice by the intravenous injection offl-propiolactone does not support the suggested
correlation. It may be argued that failure was due to insufficient fI-propiolactone
reaching the lung. However this seems unlikely, since the 10 mg. intravenous
doses were near the upper limit of toleration from the point of view of general
toxicity.
SUMMARY
1. Weekly applications of 2.5 per cent /8-propiolactone to the backs of mice
gave rise to papillomata after 27 weeks, and to epitheliomata after 40 weeks.
2. When higher concentrations (5 to 10 per cent) of fi-propiolactone were
given for the first 5 weeks, followed by weekly applications of 2.5 per cent,
ulceration and scarring occurred. In one mouse which bore a clearly visible linear
scar on the back, papillomata began to appear alongside the scar after only 7
weeks from the beginning of treatment. Three such tumours had appeared by
the 15th week, and by the 21st week all three were malignant.
3. Single intravenous injections of/8-propiolactone, in doses ranging from 1 mg.
to 10 mg. failed to increase the incidence of pulmonary adenomata, but gave rise
to severe inflammation at the site of injection, which was followed by gangrene in
some mice and scar-formation in others. Papillomata arose next to the scars in
3 of the latter.
4. These findings are discussed.
We thank Dr. M. H. Salaman for his advice. The expenses of this research
were partly defrayed out of a block grant from the British Empire Cancer
Campaign.
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